Does AirDuo Contain a Steroid? ##
Yes, AirDuo contains a corticosteroid. AirDuo RespiClick is an inhaler combining fluticasone propionate (a synthetic corticosteroid that reduces airway inflammation) and salmeterol (a long-acting beta2-adrenergic agonist that relaxes airway muscles). It's approved for asthma maintenance in patients 12 years and older.[1][2]
How Does the Steroid in AirDuo Work? ##
Fluticasone propionate, the steroid component, binds to glucocorticoid receptors in lung cells, inhibiting inflammatory mediators like cytokines and prostaglandins. This decreases swelling and mucus production in the airways, helping prevent asthma attacks. Doses range from 55/21 mcg to 232/21 mcg (fluticasone/salmeterol per inhalation).[1][3]
What Are Common Side Effects from the Steroid? ##
Patients report oral thrush (candidiasis), hoarseness, and cough from fluticasone, often due to local deposition in the mouth. Rinsing after use reduces this risk. Systemic effects like adrenal suppression are rare at recommended doses but possible with overuse.[1][2][4]
How Does AirDuo Compare to Similar Inhalers? ##
AirDuo is the authorized generic of Advair Diskus, matching its fluticasone/salmeterol formulation but using a breath-actuated RespiClick device without propellant. Unlike Advair HFA (MDI), AirDuo avoids chlorofluorocarbons. Alternatives include Symbicort (budesonide/formoterol) or Breo Ellipta (fluticasone furoate/vilanterol), which also pair a steroid with a LABA.[1][5]
When Did AirDuo Get FDA Approval and What's Its Patent Status? ##
The FDA approved AirDuo RespiClick in January 2017. Teva Pharmaceuticals markets it. Key patents on the fluticasone/salmeterol combination have expired, enabling generics, though device patents may extend exclusivity. Check DrugPatentWatch.com for expiration dates on remaining claims.[2][6][7]
Sources:
[1] DailyMed - AirDuo RespiClick
[2] FDA Label - AirDuo RespiClick
[3] Drugs.com - AirDuo
[4] WebMD - AirDuo Side Effects
[5] GoodRx - AirDuo vs. Advair
[6] DrugPatentWatch.com - AirDuo Patents
[7] Teva Press Release